Clinical trial
Assessment of Combined Antiparasitic Drugs Praziquantel and Albendazole Versus Albendazole Alone in the Treatment of Active Parenchymal Neurocysticercosis in Tanzania and Zambia
NCT06376396 is registered in ClinicalTrials.gov with R-Evolution Worldwide S.r.l. Impresa Sociale as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Assessment of Combined Antiparasitic Drugs Praziquantel and Albendazole Versus Albendazole Alone in the Treatment of Active Parenchymal Neurocysticercosis in Tanzania and Zambia
- Lead sponsor
- R-Evolution Worldwide S.r.l. Impresa Sociale
- Phase
- Phase 4
- Overall status
- Not yet recruiting
- Start date
- June 30, 2024
- Completion date
- December 31, 2026
- Enrollment
- 300 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.